| 1. |
- Wightman, D. P., et al.
(author)
-
A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease
- 2021
-
In: Nature Genetics. - : Springer Nature. - 1061-4036 .- 1546-1718. ; 53:9, s. 1276-1282
-
Journal article (peer-reviewed)abstract
- Late-onset Alzheimer’s disease is a prevalent age-related polygenic disease that accounts for 50–70% of dementia cases. Currently, only a fraction of the genetic variants underlying Alzheimer’s disease have been identified. Here we show that increased sample sizes allowed identification of seven previously unidentified genetic loci contributing to Alzheimer’s disease. This study highlights microglia, immune cells and protein catabolism as relevant to late-onset Alzheimer’s disease, while identifying and prioritizing previously unidentified genes of potential interest. We anticipate that these results can be included in larger meta-analyses of Alzheimer’s disease to identify further genetic variants that contribute to Alzheimer’s pathology.
|
|
| 2. |
- Creely, A. J., et al.
(author)
-
Overview of the SPARC tokamak
- 2020
-
In: Journal of Plasma Physics. - 0022-3778 .- 1469-7807. ; 86:5
-
Journal article (peer-reviewed)abstract
- The SPARC tokamak is a critical next step towards commercial fusion energy. SPARC is designed as a high-field (B-0 = 12.2 T), compact (R-0 = 1.85 m, a = 0.57 m), superconducting, D-T tokamak with the goal of producing fusion gain Q > 2 from a magnetically confined fusion plasma for the first time. Currently under design, SPARC will continue the high-field path of the Alcator series of tokamaks, utilizing new magnets based on rare earth barium copper oxide high-temperature superconductors to achieve high performance in a compact device. The goal of Q > 2 is achievable with conservative physics assumptions (H-98,H- y2 = 0.7) and, with the nominal assumption of H-98,H- y2 = 1, SPARC is projected to attain Q approximate to 11 and P-fusion approximate to 140 MW. SPARC will therefore constitute a unique platform for burning plasma physics research with high density (< n(e)> approximate to 3 x 10(20) m(-3)), high temperature (< Te > approximate to 7 keV) and high power density (P-fusion/V-plasma approximate to 7 MWm(-3)) relevant to fusion power plants. SPARC's place in the path to commercial fusion energy, its parameters and the current status of SPARC design work are presented. This work also describes the basis for global performance projections and summarizes some of the physics analysis that is presented in greater detail in the companion articles of this collection.
|
|
| 3. |
- Zicha, S., et al.
(author)
-
Comparative analytical performance of multiple plasma A beta 42 and A beta 40 assays and their ability to predict positron emission tomography amyloid positivity
- 2022
-
In: Alzheimers & Dementia. - : Wiley. - 1552-5260 .- 1552-5279.
-
Journal article (peer-reviewed)abstract
- Introduction This report details the approach taken to providing a dataset allowing for analyses on the performance of recently developed assays of amyloid beta (A beta) peptides in plasma and the extent to which they improve the prediction of amyloid positivity. Methods Alzheimer's Disease Neuroimaging Initiative plasma samples with corresponding amyloid positron emission tomography (PET) data were run on six plasma A beta assays. Statistical tests were performed to determine whether the plasma A beta measures significantly improved the area under the receiver operating characteristic curve for predicting amyloid PET status compared to age and apolipoprotein E (APOE) genotype. Results The age and APOE genotype model predicted amyloid status with an area under the curve (AUC) of 0.75. Three assays improved AUCs to 0.81, 0.81, and 0.84 (P < .05, uncorrected for multiple comparisons). Discussion Measurement of A beta in plasma contributes to addressing the amyloid component of the ATN (amyloid/tau/neurodegeneration) framework and could be a first step before or in place of a PET or cerebrospinal fluid screening study. Highlights The Foundation of the National Institutes of Health Biomarkers Consortium evaluated six plasma amyloid beta (A beta) assays using Alzheimer's Disease Neuroimaging Initiative samples. Three assays improved prediction of amyloid status over age and apolipoprotein E (APOE) genotype. Plasma A beta 42/40 predicted amyloid positron emission tomography status better than A beta 42 or A beta 40 alone.
|
|
| 4. |
- Beurskens, M N A, et al.
(author)
-
H-mode pedestal scaling in DIII-D, ASDEX Upgrade, and JET
- 2011
-
In: Physics of Plasmas. - : AIP Publishing. - 1070-664X .- 1089-7674. ; 18:5
-
Journal article (peer-reviewed)abstract
- Multidevice pedestal scaling experiments in the DIII-D, ASDEX Upgrade (AUG), and JET tokamaks are presented in order to test two plasma physics pedestal width models. The first model proposes a scaling of the pedestal width Delta/a proportional to rho*(1/2) to rho* based on the radial extent of the pedestal being set by the point where the linear turbulence growth rate exceeds the E x B velocity. In the multidevice experiment where rho* at the pedestal top was varied by a factor of four while other dimensionless parameters where kept fixed, it has been observed that the temperature pedestal width in real space coordinates scales with machine size, and that therefore the gyroradius scaling suggested by the model is not supported by the experiments. The density pedestal width is not invariant with rho* which after comparison with a simple neutral fuelling model may be attributed to variations in the neutral fuelling patterns. The second model, EPED1, is based on kinetic ballooning modes setting the limit of the radial extent of the pedestal region and leads to Delta(psi) proportional to beta p(1/2). All three devices show a scaling of the pedestal width in normalised poloidal flux as Delta(psi) proportional to beta p(1/2), as described by the kinetic ballooning model; however, on JET and AUG, this could not be distinguished from an interpretation where the pedestal is fixed in real space. Pedestal data from all three devices have been compared with the predictive pedestal model EPED1 and the model produces pedestal height values that match the experimental data well.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
- Deane, C. S., et al.
(author)
-
Space omics research in Europe : Contributions, geographical distribution and ESA member state funding schemes
- 2022
-
In: iScience. - : Elsevier BV. - 2589-0042. ; 25:3, s. 103920-
-
Journal article (peer-reviewed)abstract
- The European research community, via European Space Agency (ESA) spaceflight opportunities, has significantly contributed toward our current understanding of spaceflight biology. Recent molecular biology experiments include “omic” analysis, which provides a holistic and systems level understanding of the mechanisms underlying phenotypic adaptation. Despite vast interest in, and the immense quantity of biological information gained from space omics research, the knowledge of ESA-related space omics works as a collective remains poorly defined due to the recent exponential application of omics approaches in space and the limited search capabilities of pre-existing records. Thus, a review of such contributions is necessary to clarify and promote the development of space omics among ESA and ESA state members. To address this gap, in this review, we i) identified and summarized omics works led by European researchers, ii) geographically described these omics works, and iii) highlighted potential caveats in complex funding scenarios among ESA member states.
|
|
| 8. |
- Romanelli, M., et al.
(author)
-
Code Integration, Data Verification, and Models Validation Using the ITER Integrated Modeling and Analysis System (IMAS) in EUROfusion
- 2020
-
In: Fusion science and technology. - : Bellwether Publishing, Ltd.. - 1536-1055 .- 1943-7641. ; 76:8, s. 894-900
-
Journal article (peer-reviewed)abstract
- The ITER Integrated Modelling and Analysis System (IMAS) has been adopted by the EUROfusion Consortium as a platform to facilitate the analysis and verification of data from multiple tokamaks for the integration of physics codes and the validation of physics models for fusion plasma simulations. Data mapping tools have been developed to translate the tokamaks’ native data format into IMAS. The mapping required the adoption of standard coordinates, conventions on direction of vectors, signs of fields, and harmonization of physics units. The mapped data have been verified by running integrated simulations using Kepler workflows. Results of the test using IMAS data are reported here along with an assessment of the system for present and future fusion applications.
|
|
| 9. |
|
|
| 10. |
|
|
